Literature DB >> 18582622

Perfect study, poor evidence: interpretation of biases preceding study design.

John P A Ioannidis1.   

Abstract

In the interpretation of research evidence, data that have been accumulated in a specific isolated study are typically examined. However, important biases may precede the study design. A study may be misleading, useless, or even harmful, even though it seems to be perfectly designed, conducted, analyzed, and reported. Some biases pertain to setting the wider research agenda and include poor scientific relevance, minimal clinical utility, or failure to consider prior evidence (non-consideration of prior evidence, biased consideration of prior evidence, or consideration of biased prior evidence). Other biases reflect issues in setting the specific research questions: examples include straw man effects, avoidance of head-to-head comparisons, head-to-head comparisons bypassing demonstration of effectiveness, overpowered studies, unilateral aims (focusing on benefits and neglecting harms), and the approach of the industry towards research as bulk advertisement (including ghost management of the literature). The concerted presence of such biases may have a multiplicative, detrimental impact on the scientific literature. These issues should be considered carefully when interpreting research results.

Entities:  

Mesh:

Year:  2008        PMID: 18582622     DOI: 10.1053/j.seminhematol.2008.04.010

Source DB:  PubMed          Journal:  Semin Hematol        ISSN: 0037-1963            Impact factor:   3.851


  10 in total

Review 1.  Integration of evidence from multiple meta-analyses: a primer on umbrella reviews, treatment networks and multiple treatments meta-analyses.

Authors:  John P A Ioannidis
Journal:  CMAJ       Date:  2009-08-04       Impact factor: 8.262

Review 2.  Antibiotics for treating acute chest syndrome in people with sickle cell disease.

Authors:  Arturo J Martí-Carvajal; Lucieni O Conterno; Jennifer M Knight-Madden
Journal:  Cochrane Database Syst Rev       Date:  2015-03-06

3.  Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration.

Authors:  Talal Hilal; Mohamad Bassam Sonbol; Vinay Prasad
Journal:  JAMA Oncol       Date:  2019-06-01       Impact factor: 31.777

Review 4.  Haematological interventions for treating disseminated intravascular coagulation during pregnancy and postpartum.

Authors:  Arturo J Martí-Carvajal; Gabriella Comunián-Carrasco; Guiomar E Peña-Martí
Journal:  Cochrane Database Syst Rev       Date:  2011-03-16

5.  Increasing value and reducing waste in research design, conduct, and analysis.

Authors:  John P A Ioannidis; Sander Greenland; Mark A Hlatky; Muin J Khoury; Malcolm R Macleod; David Moher; Kenneth F Schulz; Robert Tibshirani
Journal:  Lancet       Date:  2014-01-08       Impact factor: 79.321

Review 6.  Interventions for preventing high altitude illness: Part 2. Less commonly-used drugs.

Authors:  Alejandro Gonzalez Garay; Daniel Molano Franco; Víctor H Nieto Estrada; Arturo J Martí-Carvajal; Ingrid Arevalo-Rodriguez
Journal:  Cochrane Database Syst Rev       Date:  2018-03-12

7.  Application of Incident Command Structure to clinical trial management in the academic setting: principles and lessons learned.

Authors:  Penny S Reynolds; Mary J Michael; Bruce D Spiess
Journal:  Trials       Date:  2017-02-09       Impact factor: 2.279

8.  Overcoming the Straw Man Effect in Oncology: Visualization and Ranking of Chemotherapy Regimens Using an Information Theoretic Approach.

Authors:  Jeremy L Warner; Peter C Yang; Gil Alterovitz
Journal:  JCO Clin Cancer Inform       Date:  2017-11

9.  Evaluation of Wearable Technology in Dementia: A Systematic Review and Meta-Analysis.

Authors:  Alanna C Cote; Riley J Phelps; Nina Shaafi Kabiri; Jaspreet S Bhangu; Kevin Kip Thomas
Journal:  Front Med (Lausanne)       Date:  2021-01-11

10.  Bibliometric Evidence for a Hierarchy of the Sciences.

Authors:  Daniele Fanelli; Wolfgang Glänzel
Journal:  PLoS One       Date:  2013-06-26       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.